For the quarter ending 2025-09-30, TBPH made $19,990,000 in revenue. $3,657,000 in net income. Net profit margin of 18.29%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 19,990,000 | 26,195,000 | 15,388,000 | 16,628,500 |
| Research and development | 8,112,000 | 10,490,000 | 11,452,000 | 9,210,500 |
| Impairment of long-lived assets (non-cash) | - | - | - | 0 |
| Selling, general and administrative | 18,333,000 | 18,430,000 | 18,370,000 | 17,621,500 |
| Total expenses | 26,445,000 | 28,920,000 | 29,822,000 | 26,832,000 |
| Loss from operations | -6,455,000 | -2,725,000 | -14,434,000 | -10,203,500 |
| Interest expense (non-cash) | 573,000 | 663,000 | 643,000 | 636,000 |
| Net gain on realized contingent milestone and royalty assets | - | 75,137,000 | - | - |
| Interest and other income, net | 4,139,000 | 1,457,000 | 939,000 | 1,169,000 |
| Income (loss) before income taxes | -2,889,000 | 73,206,000 | -14,138,000 | -9,670,500 |
| Provision for income tax benefit (expense) | -6,504,000 | 18,371,000 | -559,000 | 3,925,000 |
| Net income (loss) | 3,615,000 | 54,835,000 | -13,579,000 | -13,595,500 |
| Net unrealized gain on available-for-sale investments | 42,000 | -10,000 | -7,000 | - |
| Total comprehensive income (loss) | 3,657,000 | 54,825,000 | -13,586,000 | - |
| Earnings per share, basic | 0.07 | 1.09 | -0.27 | -0.275 |
| Earnings per share, diluted | 0.07 | 1.08 | -0.27 | -0.275 |
| Weighted average number of shares outstanding, basic | 50,520,000 | 50,177,000 | 49,706,000 | -24,469,000 |
| Weighted average number of shares outstanding, diluted | 51,908,000 | 50,726,000 | 49,706,000 | -24,469,000 |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)